ImmunoGen Inc
IMGN.O- Latest Trade
- trading higher5.39USD
- Change
- 0
- % Change
0.00%
- As of Aug 9 2022. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- 3.10 - 7.77
- Previous Close
- 5.39
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 78.20
- Shares Out (Mil)
- 220.71
- Market Cap
- 1,202.89
- Forward P/E
- -6.20
- Dividend Yield
- -99,999.99
Key Statistics
1.9 mean rating - 10 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 13.45
- Price To Book (Quarterly)
- 4.81
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -62.24
- Return On Equity (TTM)
- -44.40
2021 (millions USD)
About ImmunoGen Inc (IMGN.O)
Company Information
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Mirvetuximab soravtansine is a first-in-class ADC targeting folate receptor alpha (FRα), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. IMGN632 (Pivekimab sunirine) is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. It is advancing pivekimab in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Address
830 Winter StreetWALTHAM, MA
02451
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Stephen C. Mccluski
- Independent Chairman of the Board
- Mark Joseph Enyedy
- President, Chief Executive Officer, Director
- Susan Altschuller
- Chief Financial Officer, Senior Vice President
- Anna Berkenblit
- Senior Vice President, Chief Medical Officer
- Stacy Coen
- Senior Vice President, Chief Business Officer
- Kristen Harrington-smith
- Senior Vice President, Chief Commercial Officer
- Mimi Huizinga
- Senior Vice President, Head of Medical Affairs
- Theresa G. Wingrove
- Senior Vice President - Regulatory Affairs and Quality
- Stuart A. Arbuckle
- Independent Director
- Mark A. Goldberg
- Independent Director
- Tracey L. Mccain
- Independent Director
- Dean Jonathan Mitchell
- Independent Director
- Kristine Peterson
- Independent Director
- Helen M. Thackray
- Independent Director
- Richard J. Wallace
- Independent Director
Latest News
- MarketsBig banks, Tower Semiconductor, Huntsman Corp, travel stocks
The Nasdaq surged up to 2% and the S&P and Dow jumped more than 1% on Tuesday, as signs of a de-escalation in tensions between Russia and Ukraine pushed up megacap growth names and banks, and helped investors shrug off hotter-than expected inflation data.
- MarketsGold stocks, AMC, Tower Semiconductor, Nvidia
The S&P 500 and the Nasdaq indexes jumped over 1% on Tuesday, led by gains in shares of megacap growth names and banks on signs of a de-escalation in tensions between Russia and Ukraine, while investors shrugged off hotter-than expected inflation data.
- MarketsCrypto stocks, Virgin Galactic, Marriott, Rivian, Mastercard
U.S. stock indexes were set for a stronger open on Tuesday, led by gains in shares of megacap growth names and banks on signs of a de-escalation in tensions between Russia and Ukraine.
- MarketsDidi, MEI Pharma, TG Therapeutics, Cumberland Pharma
Wall Street's main indexes tumbled more than 1% on Tuesday after Federal Reserve Chair Jerome Powell said the risk of higher inflation has increased and that it was appropriate to consider wrapping up tapering of bond purchases a few months sooner.
- MarketsFacebook, Tesla, Regeneron Pharma, ImmunoGen
Wall Street's main indexes were set to fall sharply on Tuesday after a warning from vaccine maker Moderna's chief executive on the effectiveness of COVID-19 shots against the Omicron variant hammered travel, energy and banking shares.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,789.00 | 0.12%Positive |
| Copper | 665.30 | 0.40%Positive |
| Brent Crude Oil | 97.98 | 1.38%Positive |
| CBOT Soybeans | 1,656.00 | 2.25%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,140.06 | -- |
| Euro STOXX 50 | 3,727.25 | 0.80%Negative |
| FTSE 100 | 7,481.80 | 0.01%Negative |
| Nikkei 225 | 27,999.96 | 0.88%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes